NeuroSense Therapeutics Ltd. (NRSN) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
17
First IPO Date
December 09, 2021
| Name | Title | Pay | Year Born |
| Alon Ben-Noon | Co-Founder, Chief Executive Officer & Director | 392,000 | 1979 |
| Niva Russek-Blum | Chief Technology Officer | 201,000 | 1979 |
| Or Eisenberg | Chief Financial Officer | 273,000 | 1981 |
| Ferenc Tracik | Chief Medical Officer | 447,000 | 1964 |
| Yael Barak | Vice President of Quality & Compliance | 0 | 1970 |
| Keren Pushett | Head of HR | 0 | N/A |
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.